Two Boston-based researchers shared methods for detecting circulating nucleic acid biomarkers for potential use in cancer diagnosis and monitoring.
They plan to combine Silicon’s DEPArray digital-sorting technology with Macrogen’s NGS systems to develop genomic tests for different cancers.
Their clinical trial will compare the effectiveness of tissue biopsies and liquid biopsies for tumor detection and monitoring.
The financing round has an option for an additional $10 million investment.
The company anticipates releasing initial data this year showing that is cancer of unknown primary origin test can successfully guide treatment decisions.
The results suggest comprehensive sequencing like Foundation Medicine's could potentially help improve outcomes for patients with widespread cancer of unknown primary origin.
NEW YORK (GenomeWeb) – Rosetta Genomics has initiated a patient registry study for its Cancer Origin Test, the company announced this week.
This story has been updated to clarify the current state of the Tissue of Origin test formerly of Pathwork Diagnostics, now owned and marketed by Response Genetics.
Rosetta Genomics this week announced the publication of data demonstrating the involvement of certain microRNAs in epithelial-mesenchymal transition, or EMT, in cancers of unknown primary origin.
NEW YORK (GenomeWeb News) –Rosetta Genomics today announced it has executed credentialing agreements with two preferred provider organizations for its Cancer Origin Test.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.